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E-mail: galy@genethon.frGenetic deficiency of the nuclease DCLRE1C/Artemis causes
radiosensitive severe combined immunodeficiency (RS-SCID)
with lack of peripheral T and B cells and increased sensitivity
to ionizing radiations. Gene therapy based on transplanting
autologous gene-modified hematopoietic stem cells could
significantly improve the health of patients with RS-SCID by
correcting their immune system. A lentiviral vector expressing
physiological levels of human ARTEMIS mRNA from an EF1a
promoter without post-transcriptional regulation was devel-
oped as a safe clinically applicable candidate for RS-SCID
gene therapy. The vector was purified in GMP-comparable
conditions and was not toxic in vitro or in vivo. Long-term
engraftment of vector-transduced hematopoietic cells was
achieved in irradiated Artemis-deficient mice following
primary and secondary transplantation (6 months each).
Vector-treatedmice displayed T and B lymphopoiesis and poly-
clonal T cells, had structured lymphoid tissues, and produced
immunoglobulins. Benign signs of inflammation were noted
following secondary transplants, likely a feature of the model.
There was no evidence of transgene toxicity and no induction
of hematopoietic malignancy. In vitro, the vector had low gen-
otoxic potential on murine hematopoietic progenitor cells
using an immortalization assay. Altogether, these preclinical
data show safety and efficacy, and support further development
of the vector for the gene therapy of RS-SCID.
INTRODUCTION
Among severe combined immunodeficiency (SCID), rare cases of
radiosensitive SCID (RS-SCID)1 are caused by loss-of-function muta-
tions in the DNA cross-link repair enzyme 1C (DCLRE1C) gene, also
known as the ARTEMIS gene (OMIM: 602450).2 Such cases of T-B-
NK+ SCID present early in life with severe infections, diarrhea, and
failure to thrive. Patients demonstrate increased radiosensitivity and232 Molecular Therapy: Methods & Clinical Development Vol. 15 Decem
This is an open access article under the CC BY-NC-ND license (httpan autosomal recessive pattern of inheritance. Artemis is a ubiqui-
tously found nuclear protein, which is a member of the metallo-
beta-lactamase superfamily of nucleases used to repair DNA dou-
ble-strand breaks (DSBs).3 By digesting DNA overhangs and DNA
hairpins, Artemis is a key factor for the non-homologous end joining
(NHEJ) mechanism that is used to repair DSBs during all phases of
the cell cycle and used to rearrange the T cell receptor (TCR) and
immunoglobulin (Ig) genes during T and B lymphoid development.4
Artemis also controls DNA replication efficiency by breaking DNA in
stalled replication forks, thereby limiting chromosomal instability.5
Conventional treatment of RS-SCID is based on the transplantation
of allogeneic hematopoietic stem cells (HSCs) to restore T and B lym-
phopoiesis and to provide adaptive immune function in treated
patients. Allogeneic HSC transplant from matched family donors
provides a survival probability greater than 85% in RS-SCID patients
and about 65% for haplo-identical transplants.6 However, compared
with other SCIDs, the allo-HSC-transplanted RS-SCID patients have
high rates of complications including late complications such asber 2019 ª 2019
://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Artemis LV and Schematic Design of Mouse Transplant
Experiments
(A) EF1a-hArtemis LV construct. A self-inactivated HIV-1-derived LV (pCCL back-
bone) expressing human ARTEMIS cDNA under control of the EF1a promoter. (B)
Purified bone marrow (BM) Sca-1+ cells from ART_KO orWTmice were transduced
by EF1a-hArtemis or PGK-eGFP LV at the concentration of 1E+8 IG/mL for one or
two hits of infection, and 2E+5 cells/mice were transplanted into irradiated
primary recipient ART_KO mice. Two groups of 10 mice each received cells
transduced with one or two hits of EF1a-hArtemis LV (groups ART_GT 1hit and
ART_GT 2hits). A control treatment group of 10 mice received GFP-transduced
ART_KO Sca-1+ BM cells from which no functional correction was expected (group
ART_KO GFP). A positive control treatment group of eight mice received GFP-
transduced WT cells that were expected to restore immune development (group
WT_GFP). Primary transplanted mice were followed up for up to 6 months at which
point the BM cells from each of the surviving animals were transplanted into two
secondary recipients (irradiated ART_KO female mice) for a longitudinal follow-up of
6 months (68 mice total). Longitudinal follow-up of the mice included regular ob-
servations, weighing, blood counts, measures of engraftment and transduction,
and autopsy and histology at sacrifice. In addition to the treated mice, primary and
secondary transplant experiments also included control non-transplanted groups
with irradiated and non-irradiated ART-KO mice providing background results
(groups ART_KO and ART_KO irr) and non-irradiated WT mice for normal com-
parison (group WT).
www.moleculartherapy.orggrowth delay and nutritional problems.6,7 Autologous gene therapy
based on the transplantation of gene-corrected autologous HSC is
an option for RS-SCID patients without human leukocyte antigen
(HLA)-compatible donors, although late complications concerning
non-hematopoietic tissues are not expected to be avoided by gene
therapy.Molecular TheSeveral groups including ourselves have already shown that recombi-
nant HIV-1-derived lentiviral vectors (LVs) can be used to express
either murine or human Artemis proteins in hematopoietic cells to
restore B and T lymphopoiesis in murine models of RS-SCID or in
xeno-transplant models engrafted with transduced patient cells.8–12
High levels of Artemis expression appear to be toxic in vitro and
in vivo.11,13,14 Loss of cell viability, perturbed cell cycle, increased
DNA damage, and apoptosis were reported in cultured murine or hu-
man cell lines transduced with LV that strongly express either human
or murine Artemis.13 The in vitro effects were vector dose dependent
and correlated to the strength of the promoter used in the Artemis
transfer cassette. The strong elongation factor-1a (EF1a) promoter
caused greater in vitro toxicity than the weaker human phosphoglyc-
erate kinase (PGK) promoter, which is about 25% less strong in a lucif-
erase reporter assay.11 Artemis-deficient HSC transduced by a LV with
amurine PGK promoter driving expression of murineArtemis success-
fully engrafted in vivo and reconstituted B and T lymphocyte compart-
ments in Artemis-deficient mice,8 whereas HSC transduced with a LV
using stronger cytomegalovirus (CMV) or EF1a promoters failed to
support lymphoid reconstitution after transplantation in RAG-1-defi-
cient animals.10
Thus, a safe and clinically applicable Artemis LV should express
transgene levels that are non-toxic and corrective. One option is to
use the ARTEMIS gene promoter consisting of a 1-kb sequence up-
stream of the translational start site,15 which provides a much weaker
(about 80% less) expression than the EF1a promoter in a luciferase re-
porter assay.11 LVs expressing ARTEMIS from its own promoter were
not toxic in vitro or in vivo, enabling lymphoid reconstitution in
Artemis-deficient mice.11,12 The strategy that we chose to develop is
to use the EF1a promoter, which has been used in several human
gene therapy trials for SCIDs, but to omit the woodchuck post-tran-
scriptional regulatory element (WPRE) in the expression cassette.
WPRE can increase transgene levels by at least 2-fold in other sys-
tems.16 All of the previously tested Artemis expression cassettes
that were found to cause toxicity included a WPRE.10,11,13 We found
that expressing the ARTEMIS cDNA under control of EF1a promoter
and without WPRE (EF1a-hArtemis LV) provided physiologically
relevant levels of Artemis expression that permitted safe long-term
engraftment and lymphoid correction in Artemis-deficient mice.
Gene therapy-treated Artemis-deficient mice were analyzed for a
period of up to 1 year through primary and secondary transplants.
In parallel, the vector was also tested in an in vitro immortalization
(IVIM) assay using murine hematopoietic progenitor cells to estimate
the vector genotoxicity as previously reported.17 Results in mice sug-
gest that the EF1a-hArtemis LV would be a safe and efficient vector
for the gene therapy of RS-SCID.
RESULTS
A Self-inactivating LV for RS-SCID Gene Therapy
The vector tested in the present study is an advanced self-inactivated
HIV-1-derived LV (pCCL backbone) expressing the native ARTEMIS
cDNA under control of the short intronless EF1a promoter, without
WPRE (Figure 1A). The WPRE was omitted because Artemisrapy: Methods & Clinical Development Vol. 15 December 2019 233
Molecular Therapy: Methods & Clinical Developmentoverexpression reportedly prevents engraftment of transduced
murine hematopoietic cells.11,13 Indeed, adding a WPRE (Figure 1A,
position *) strongly enhanced Artemis mRNA expression by about
5-fold per copy of integrated vector when tested in human fibroblasts
derived from a RS-SCID subject, compared with the vector lacking
this element (Figure S1A). These differential effects were confirmed
at the protein level (Figure S1B) and prompted us not to choose
this vector. To estimate the strength of the vector expressing
ARTEMIS and lacking WPRE, we transduced Artemis-deficient
mouse cells with this vector and compared expression against levels
found in normal mice using a standardized qRT-PCR system cali-
brated on a plasmid containing both human ARTEMIS and murine
Artemis genes sequences. This method showed that two copies of
the EF1a-hArtemis vector per cell were needed to obtain transgene
mRNA levels equivalent to those found in normal murine hematopoi-
etic cells (Figure S1C). Based on these results and data from the liter-
ature, it was reasonable to expect that the EF1a-hArtemis LV could
function in a physiologically relevant and safe manner to correct
the T and B cell defects of Artemis-deficient mice.
Biosafety Study Design
A formal preclinical study was designed to evaluate the efficiency and
safety of the EF1a-hArtemis LV in primary and in secondary trans-
planted Artemis-deficient mice as outlined in Figure 1B. The design
of long-term observations, 1 year in total, was previously used in pre-
clinical protocols of gene therapy aiming to reveal vector-induced
insertional mutagenesis or transgene toxicity.8,18,19 Engraftment
was measured by the levels of male donor cells into female recipient
mice as previously reported.20 The protocol also measured transduc-
tion and transgene expression levels, functional correction, health
status, hematological parameters and occurrence of tumors. For these
studies, we generated a quality-controlled batch of EF1a-hArtemis
LV, which was produced and purified in conditions similar to other
clinical-grade LV vectors produced at Genethon.21 The purified
EF1a-hArtemis LV was sterile, had low levels of DNA and protein
contaminants, and lacked replicative particles (Table S1). A PGK-
eGFP LV that was also prepared and purified in the same conditions
was used as a transduction efficiency control.
Sca-1+ hematopoietic progenitor cells were used for the transplant
experiments outlined in Figure 1B, because this population enriched
in progenitor cells is known to engraft and to restore T and B
lymphoid development and function following transduction with a
murine Artemis transgene.8 In two separate experiments, Sca-1+
bone marrow (BM) progenitor cells obtained from male Artemis-
deficient (ART_KO) mice were efficiently transduced with the
EF1a-hArtemis LV (Table S2A), and these cells were transplanted
in female ART_KO mice. Efficient transduction was confirmed
with the PGK-eGFP LV, which provided a similar range of VCN
values as the EF1a-hArtemis vector and showed 65%–70% GFP-
positive cells in the bulk cultures (Table S2A). One or two cycles of
infection (hits) provided on average 1.4 vector copy numbers per
cell (VCNs) in cells after bulk culture. The effects of repeated infection
with the Artemis vector were more evident on more primitive cell234 Molecular Therapy: Methods & Clinical Development Vol. 15 Decemtransduction providing, respectively, between 1 and 2.2 VCNs in
clonogenic hematopoietic progenitor cells, and Artemis transgene
expression levels that were between 32% and 47% of normal
C57BL/6 wild-type (WT) cell levels (Table S2A). Individually picked
colonies confirmed that repeated transduction increased the fre-
quency of transduced hematopoietic progenitor cells and increased
their transduction levels because 91% positive colonies with an
average of 2.3 VCNs were obtained after two hits versus 86% positive
colonies with 1.4 VCNs after one hit of vector (Tables S2A and S2B).
None of the vectors tested altered the hematopoietic differentiation
and clonogenic potential of the cells as measured by colony-forming
unit (CFU-C) cell counts (data not shown).
Primary transplanted mice were followed up for up to 6 months, at
which point the BM cells from each of the surviving animals were
transplanted into two secondary recipients for a longitudinal addi-
tional follow-up of 6 months. In the EF1a-hArtemis-LV-treated
groups, between 0.6 and 10 (average 4E+6) male donor BM cells
(BMCs) were secondarily transplanted, corresponding to the infusion
of an average of 7E+3 transduced hematopoietic progenitor cells per
mouse, containing 2.3 ± 1.2 VCNs per cell (Table S3).
In Vivo Engraftment of Transduced Cells and Correction of the
Artemis Phenotype
The engraftment of gene-modified donor cells was observed following
primary or secondary transplants in groups treated with one or two
hits of the EF1a-hArtemis LV (Figures 2A–2H). Donor chimerism
(Figures 2A–2D) and vector integration (Figures 2E–2H) were de-
tected in various hematopoietic and lymphoid organs, but not in
non-hematopoietic tissues such as ovaries, as measured by qPCR.
Transduction levels in vivo ranged between two and four copies per
cell, according to the organs tested. Levels of engraftment with trans-
duced donor cells were higher in primary transplant (ranging from
50% to 80% on average) than in secondary transplants (from
10%–65% on average depending on the organs). Lower levels of
engraftment in secondary transplants, particularly in the BM, were
not specific for the EF1a-hArtemis LV because this also occurred
with the PGK-eGFP LV (Figures S2A–2H). The markedly higher
engraftment level in lymph nodes, and to a lesser extent in thymus,
compared with BM could be a feature of the model, which is using
sublethal irradiation conditioning that limits myelo-erythroid
engraftment in BM. Transplanting whole BMCs in secondary grafts
provided a relatively low number of hematopoietic progenitor cells
(between 0.2 and 1.4E+4 donor colony forming cells (CFCs) per
mouse; Table S3), which limits engraftment in BM. Alternatively,
the BMCs infused for the secondary grafts could have contained
immature or mature T cells that engrafted preferentially in the sec-
ondary hosts. Indeed, after secondary transplant, lymph nodes
contained greater than 50% of donor-derived transduced cells in
groups treated with the EF1a-hArtemis LV, indicating that trans-
duced lymphoid cells can persist for long periods of time (Figure 2).
Transgene expression was detected at various levels in lymphoid





Figure 2. Engraftment and Transduction Levels in
Primary and Secondary Grafts
Primary (A, C, E, and G) and secondary (B, D, F, and H)
grafts show the percentage of donor cells measured by Y
chimerism in different tissues and the level of transduction
measured in by VCN, respectively, in the ART GT 1Hit
group (A, B, E, and F) and ART GT2Hits group (C, D, G,
and H). VCN was determined by qPCR and normalized
for the percentage of engraftment. Each data point is from
a single mouse. Horizontal bars represent mean values.
www.moleculartherapy.orgtransplantation (Figures 3A–3F). In primary grafts, for instance,
54% ± 25% and 41% ± 23% relative expression of ARTEMIS
mRNA was measured in the spleen of mice treated, respectively,
with one or two hits of EF1a-hArtemis LV, compared with 0%
mRNA in the negative control groups and 117% ± 58% mRNA in
mice treated by WT cells (Figures 3A, 3C, and 3E). In the BM, about
half as much ARTEMIS mRNA was provided by the EF1a-hArtemis
LV transduction compared with WT cells (50% ± 20% in WT_GFP
mice versus 21% ± 13% in ART-GT one-hit mice and 25% ± 18%
in ART-GT two-hit mice). In secondary grafts, ARTEMIS mRNA
expression was generally lower than in primary grafts but still detect-Molecular Therapy: Methods & Clinicable in BM, spleen, thymus, and lymph nodes in
EF1a-hArtemis LV-treated mice (Figures 3B,
3D, and 3F). In the spleen, 9.4% ± 8%, 19% ±
12%, and 66% ± 13% of relative mRNA are
found, respectively, in mice treated with one
or two hits of EF1a-hArtemis LV and with
WT cells. Following secondary transplants, the
lymph nodes were highly reconstituted, ex-
pressing similar levels of ARTEMIS mRNA
in mice treated with one or two hits of EF1a-
hArtemis LV or with WT cells (65% ± 36% in
ART-GT one-hit mice and 83% ± 21% in
ART-GT two-hit mice versus 81% ± 13% in
WT-GFP mice). Some mice developed tumors
from donor-derived transduced cells (as dis-
cussed below), and values of mRNA for these
mice are represented by open symbols in
Figure 3. Outlier mRNA values corresponding
to tumor samples were not included in the
mRNA level group comparisons.
Gene therapy with the EF1a-hArtemis LV
restored T cell development. The recovery
of thymopoiesis was evident in ARTEMIS
gene therapy-treated mice, particularly in pri-
mary transplants. The number of CD4+CD8+
double-positive thymocytes per thymus 
E+03 was 11,383 ± 13,201 and 7,471 ±
8,656 in mice treated with one and two hits
of Artemis vector, respectively, as comparedwith 464 ± 575 cells in GFP-treated Artemis-deficient negative
controls, with these values excluding mice with thymomas. Thymic
recovery was also evident by strong immunohistological marking
of CD3 throughout the thymus in ARTEMIS gene therapy-treated
mice, whereas the staining was very low to absent in Artemis-defi-
cient controls (Figure S3). Correction of T cell development was
also shown by the presence of statistically higher numbers of
CD3+CD4+ and CD3+CD8+ T cells in lymphoid organs such as
the spleen (Figures 4A–4D), whereas control ART-KO mice had
very few T cells. The effects of one or two hits of transduction

































































































































































































Primary graft Secondary graft Figure 3. ARTEMIS mRNA Expression after Primary
and Secondary Engraftment
Primary (A, C, and E) and secondary (B, D, and F) grafts
show ARTEMIS mRNA levels in hematopoietic and
lymphoid tissues in the WT GFP group (A and B), ART
GT1hit group (C and D) and ART GT2Hits group (E and F).
(A–F) Each data point is from a single mouse. Open
symbols correspond to mice that developed tumors from
donor-derived transduced cells. Horizontal bars repre-
sent mean values.
Molecular Therapy: Methods & Clinical Developmentthat two hits provided higher levels of CD4+ T cells in secondary
transplants (Figure 4B). TCR Vb diversity was measured by PCR
and confirmed that ART-KO mice used in these experiments
and that have a severe block in T cell development have a very
limited, oligoclonal, and skewed TCR repertoire with a representa-
tion of V12-J1.5, V13-J2.7, and V05-J2.5 TCR b chain usage.2,22
After irradiation, TCR diversity was around 6% in the spleen (Fig-
ure 4E). Following gene therapy, the EF1a-hArtemis LV restored a
polyclonal pool of CD3+ T lymphocytes with a T cell repertoire
(TCR) b chain diversity of 54%–71% and 46%–78%, respectively,
in groups treated with one and two hits of vector (Figure 4E).236 Molecular Therapy: Methods & Clinical Development Vol. 15 December 2019These values remained inferior to what was
observed in mice treated with WT cells that
had a TCRb diversity of 85% in spleen (data
not shown). The same V12-J1.5, V13-J2.7,
and V05-J2.5 detected in ART-KO
mice were still detected in mice treated by
ARTEMIS gene therapy but no longer repre-
sented a majority of the Vb usage. Increased
numbers of TCRgd+ T cells were also
observed in EF1a-hArtemis LV-treated mice
compared with negative controls (data not
shown).
Gene therapy with the EF1a-hArtemis LV also
significantly restored B lymphocyte develop-
ment, although B cell recovery was not as high
as in mice treated by WT cells (Figures 5A–
5D). However, the presence of CD19+IgM+
and CD19+IgD+ cell populations was detectable
over background in the blood (data not shown)
and was significantly higher in the spleen of
mice treated with two hits of the EF1a-hArtemis
LV compared with GFP-treated mice in pri-
mary and secondary transplants (Figures 5A–
5D). Circulating levels of IgM and IgG were
detected in the sera of mice treated with the
EF1a-hArtemis LV and were similar to the
levels found in WT mice or mice treated with
WT cells, whereas IgG and IgM were undetect-
able in negative control mice (Figure 5E).
Furthermore, immunohistological staining ofspleens in EF1a-hArtemis LV-treatedmice was structured (Figure 6A)
and showed the presence of B220+ cells organized in B cell follicles
(Figure 6B) surrounding CD3+ T cell-dense areas indicative of
germinal centers (Figure 6C). The splenic organ structuration of B
cell and T cell areas was clearly induced by EF1a-hArtemis LV gene
therapy, although it was not as marked as in mice treated with WT
cells. Altogether the results show that EF1a-hArtemis LV enables effi-
cient engraftment and secondary transplantation, and induces partial
but effective recovery of Artemis mRNA expression capable of
inducing T and B cell development with possible immune function














































































































































































































Figure 4. T Lymphocyte Reconstitution in Spleen
from Recipient Mice Treated by ARTEMIS Gene
Therapy
Mice were analyzed after 6 months of transplantation for
T phenotype in hematopoietic organs. Representative
recovery of CD3+CD4+ (A and B) and CD3+CD8+ (C and
D) cells in spleen of recipient female ART_KO mice from
primary (A and C) and secondary graft (B and D). (A–D)
Each data point is from a single mouse. Horizontal bars
represent mean values. p values were calculated with a
Mann Whitney test. (E) Analysis of T cell receptor Vb
(TRVB) repertoire in the spleens of primary grafts with a
3D representation. Each peak represents a rearrange-
ment between a family of V genes and a J segment. The
x axis represents TRBV, y axis represents TRBJ, and
z axis represents the relative intensity of the signal.
www.moleculartherapy.orgEvaluation of Health in Artemis-Treated Mice
Blood counts, hemoglobin, and hematocrit were measured 3 and
6 months post-transplantation to assess the health of mice. Besides,
mice were regularly observed for health status and weight. In the
follow-up of primary and secondary transplants, there was no differ-
ence in any of the groups for red blood cell (RBC) counts (Figure S4),
hemoglobin, and hematocrit parameters (data not shown). The levels
of leukocytes (white blood cells [WBCs]), which are lower in Artemis-
deficient mice compared with WT mice, were significantly increased
by gene therapy (p < 0.001) after primary transplants (Figure 7A),
although not as high as in mice treated with WT cells, in coherence
with partial restoration of T and B cell levels (Figures 5 and 6). Plate-
lets counts were not significantly different among groups in primary
grafts (Figure 7C) but were clearly increased in the Artemis-treated
mice after secondary transplants (Figure 7D). Such an increase coin-
cided with higher levels of WBCs, although these were not higher
than in WT mice (Figure 7B). These increased WBC counts were
not due to the occurrence of malignancies, and mice with tumors
will be detailed below. Such biological data suggested possible inflam-Molecular Therapy: Methods & Clinimation, which is known to increase WBC and
platelet counts. Indeed, in secondary trans-
planted mice we detected low levels of circu-
lating inflammatory cytokines such as inter-
feron-g (IFN-g), interleukin-6 (IL-6), and
tumor necrosis factor alpha (TNF-a), which ap-
peared to be at higher levels than in Artemis-
deficient non-treated controls, but some of
these cytokines were found at the same levels
in WT mice (Table S4). The sanitary status of
the animals and of the facility was verified,
and there were no detectable infectious agents
detected at the time of the experiments. In the
mice without tumors, the appearance and
behavior of the animals were unremarkable.
Some weight differences were noted among
groups. Compared with WT mice, which weigh
about 20 g between 6 and 8 weeks of age anddisplay a moderate weight gain over time, Artemis-deficient mice
were slightly heavier at start and continuously gained weight over
time, even after irradiation, reaching body weights over 30 g after
6 months (data not shown). The transplantation ofWT cells into irra-
diated ART_KO mice did not modify their increasing body weight
curve, whereas EF1a-hArtemis LV-treated mice normalized their
weight curve, which was the same, and not below, that of WT mice
(data not shown). Analysis of individual mice showed no correlation
between cytokine levels, body weight, or platelet counts (data not
shown). We conclude that EF1a-hArtemis LV-treated mice do not
suffer from acute hematopoietic or immune toxicity.
No Evidence of Oncogenic Potential of the EF1-hArtemis LV
The ART-KO mice are tumor prone in the conditions used, but the
protocol aimed to evaluate whether the Artemis vector caused an
additional risk for oncogenicity. As expected, in the irradiated
ART_KO group, the background level of tumors found within a
6-month period was 35%, which is a high level, consistent with the
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Figure 5. B Lymphocyte Reconstitution in Spleen
and Sera from Recipient Mice Treated by Artemis
Gene Therapy
As previously described, mice were analyzed also for B
phenotype in hematopoietic organs after 6 months of
transplantation. Representative recovery of CD19+IgM+
and CD19+IgD+ cells in spleen of recipient female
ART_KO mice from primary (A and C) and secondary
graft (B and D). (A–D) Each data point is from a single
mouse. Horizontal bars repreesent mean values. p values
were calculated with a Mann-Whitney test. (E) Evaluation
of IgM and IgG in serum of mice from the primary graft.
Data are represented as mean ± standard deviation.
Molecular Therapy: Methods & Clinical Developmentthe EF1a-hArtemis LV-treated groups there were 20%–25% animals
with tumors, which was not higher than any other group. All of the
tumors identified in any of the groups were T cell lymphomas,
variously expressing CD3, CD4, or CD8, which were either localized
thymomas or disseminated in all lymphoid organs and sometimes in
liver as mice displayed signs of splenomegaly and hepatomegaly
(Table S5A). Molecular analyses could determine the origin of the
tumors by detecting if they consisted of donor male cells or contained
significant levels of vector copies. In total, 19 treated mice out of 88
(22%) were found to bear lymphomas regardless of groups of treat-
ment, which was not higher than the background ART_KO irradiated
control group (Table 1). Most tumors originated from host non-
transduced cells as in the control group. Yet, six treated mice were
found to have tumors originating from donor-derived transduced
cells. Two of these tumors were transduced with the PGK-eGFP vec-
tor. Four mice had tumors with the EF1a-hArtemis LV, two of which238 Molecular Therapy: Methods & Clinical Development Vol. 15 December 2019arose in primary transplants (Table 1). One of
these mice was unrecognized at the time and
served as a BM donor, transmitting the tumor
to the two mice generated by secondary trans-
plants. The origin of the tumors with the
EF1a-hArtemis LV was tracked by the analysis
of vector insertion sites (ISs). One of the two
primary graft tumors was a disseminated lym-
phoma that had three dominant vector inser-
tions in Jmjd1c, Dnah8, and Dach2 genes, and
these insertions were also identified in the sec-
ondary transplant tumors derived from this an-
imal (Figure 8; Table 1; Table S5B). The other
tumor was a localized thymoma that had two
insertion sites in Hspa41 and Unc13c genes,
and an intergenic IS mapped on the chr8
72,292,582. These insertions were not
frequently represented in the other organs
analyzed, confirming that the tumor was
restricted to the thymus (Figure 8A). In the
spleen and BM of this animal, a high number
of diverse vector IS insertion sites was found
as expected from the polyclonal population of
cells and from the histological evaluation ofthese tissues that appeared to be normal (Table S5B). In addition, an-
imals transplanted with the BM from this animal did not develop tu-
mors. None of the gene insertions that were identified in tumor cells
or in normal tissues analyzed in the whole study were found to be on-
cogenes or associated with known T cell lymphoma processes as
determined by interrogation of the AmiGO2 MGI (Mouse Genome
Informatics), and NCBI databases. Some of the gene vector insertions
found in tumors (jmjd1c, hspa4l, dach2) or in non-tumoral tissue
(qk) have previously been reported as sites of LV insertion in the mu-
rine genome.23,24
To complete the evaluation of the oncogenic potential of the
EF1a-hArtemis LV, we performed an IVIM assay as described.17
The assay detects the induction of a survival advantage and transfor-
mation by insertional activation of cellular proto-oncogenes




Figure 6. Histological Evaluation (4) of Spleen from Recipient Mice
Treated by Artemis Gene Therapy in Comparison with the WT or ART_KO
Control Mice
Representative sections of spleen from the indicated groups (top) treated with H&E
staining (A) or immunostaining for B220 (B) or immunostaining for CD3 (C).
www.moleculartherapy.orgLTR-driven gamma-retroviral vectors such as pRSF91.GFPgPRE
(RSF91) or SIN-LVs with strong internal promoters like
RRL.PPT.SF.eGFP.pre* (LV-SF). In three independent IVIM assays,
there was no detection of mutagenic potential from the EF1a-hArte-
mis LV (Figure 8B). Altogether, we conclude that there is no evidence
of oncogenic potential from the EF1a-hArtemis LV and that, in some
cases, transduction with the vector could be passively associated to,
but not causative of, the oncogenic processes that can occur in
Artemis-deficient cells.
DISCUSSION
The present study is the first preclinical and comprehensive biosafety
evaluation of a LV developed for the gene therapy of RS-SCID. This
controlled study using a GMP-comparable vector with extensive sur-
vey of the health and biological parameters of treated mice provides
additional information to previous reports showing that hArtemis-
encoding LV can correct Artemis deficiency in mice.11,12 It is shown
that removing the WPRE decreased the level of expression to a safer
level. Indeed, the EF1a-hArtemis LV expressed low but functional
levels of Artemis that were not toxic in vitro or in vivo on murine he-
matopoietic cells, enabling long-term engraftment up to 1 year in sec-
ondary transplants in mice, and reconstituting T and B cell develop-
ment without evidence of vector-induced toxicity on blood
parameters, or of vector-induced mutagenesis. The lack of toxicity
of the EF1a-hArtemis LV was also confirmed in vitro on
human cells, causing no effect on cell growth, cell viability, and clono-
genicity following transduction of umbilical cord blood CD34+
hematopoietic progenitor cells (data not shown). In contrast, the
same vector with WPRE expressed greater levels of hArtemis, which,Molecular Thebased on prior reports with a similar vector, would be expected to
hamper engraftment of transduced cells. There is no direct molecular
mechanism linking high Artemis expression with cellular or
hematopoietic toxicity, and the toxicity of high Artemis levels is
only inferred from correlative studies with different promoter sys-
tems.10–12 Artemis transgenic mice expressing up to 40 times more
Artemis than WT mice do not display hematopoietic or lymphoid
anomalies.22 In addition, hematopoietic progenitor cells of normal
mice that were transduced to overexpress Artemis engrafted success-
fully (data not shown). Thus, mechanisms causing in vivo or in vitro
toxicity observed with the strongly expressing Artemis vectors should
be further studied to determine whether other parameters could be
involved in the lack of engraftment that was observed. At the practical
level, our study has established disease correction and no adverse
events related to the vector. Such EF1a-hArtemis vector is a good
candidate to further develop for clinical use in humans. Because it
lacks unnecessary viral element (WPRE), it reduces the integration
of foreign DNA sequences in the genome of patients. It is using a pro-
moter that has already been used in successful lentiviral gene therapy
trials in humans in other types of SCIDs,25 and it can be produced in
GMP-comparable conditions demonstrating its ability to correct the
disease phenotype in mice without acute toxicity.
Treatment of Artemis-deficient mice with the EF1a-hArtemis LV
releases the T and B cell differentiation block caused by Artemis
deficiency as reported in other studies using LV with murine8 or hu-
man Artemis10–12 transgenes. As a consequence, it also normalizes
the natural killer (NK) cell counts, which were higher in non-treated
Artemis-deficient mice (data not shown). Reconstitution of T cells,
and particularly of peripheral T cells, was very effective at inducing
high cell counts, thymopoiesis, and a polyclonal TCR repertoire, be-
ing equivalent to that obtained with LV using the Artemis pro-
moter.11,12 B cell levels were only partially corrected in BM or spleen.
Yet, EF1a-hArtemis LV clearly restructured T and B cell zones in
lymphoid tissues in treated animals including appearance of bron-
chus-associated lymphoid tissue (data not shown) and the production
of Igs. The relatively low correction of B cell numbers by EF1a-hAr-
temis gene therapy is likely due to intrinsic limitations of the murine
model. Indeed, differential T/B reconstitution and limited B cell re-
covery were also observed following BM transplant in Artemis-defi-
cient mice.26 Poor B cell reconstitution following gene therapy was
also seen with the Artemis promoter LV studies in mice in which
about 1% donor-derived transduced B cells were recovered in blood
compared with about 12% following infusion of WT cells.12 The
EF1a-hArtemis LV achieved about 3%–4% donor B cells in blood
versus 60% from WT cells. In BM, 3%–4% donor CD19+ B cells
were obtained versus about 14% from WT cells, and these levels are
similar to that reported with the Artemis promoter LV. Whereas B
cell reconstitution is low in murine transplantation models, on the
contrary, human HSC transplant studies using the NSGmouse model
support efficient B cell differentiation and have shown that the
ARTEMIS gene promoter enables the development of high levels of
transduced B cells, comparable with WT cells.12 Thus, in spite of lim-
itations of the models, we expect that the EF1a-hArtemis LV, whichrapy: Methods & Clinical Development Vol. 15 December 2019 239
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Figure 7. Peripheral Blood Count Analysis before the
Sacrifice of the Recipient Mice after Primary and
Secondary Engraftment
Primary (A and C) and secondary (B and D) graft analysis of
white blood cell (WBC) (A and B) and platelets (C and D)
blood counts as determined with an automated cell
counter. Each data point is a single mouse. Horizontal bars
represent mean values.
Molecular Therapy: Methods & Clinical Developmenthas a similar effect to the ARTEMIS promoter LV in mice, will also
correct human B cells, but this will have to be demonstrated in future
studies. We can speculate that gene therapy with the EF1a-hArtemis
LV should improve the immune status of patients because the
ARTEMIS promoter LV, which leads to a similar reconstitution in
mice, permits functional recovery of immune responses as measured
by antigen-specific T cell proliferation and antibody production.12
Adverse events could occur following gene therapy. There is a
known association between Artemis deficiency and lymphomas,
particularly aggressive B cell lymphomas in patients with hypomor-
phic Artemis mutations. Yet, lymphomas are not particularly
increased in human RS-SCID patients treated by HSC transplant,
so this suggests that the risk for adverse events such as lymphoma
would not be significantly increased by gene therapy. Indeed, the
risk for oncogenesis by insertional mutagenesis or by overt trans-
gene toxicity did not manifest in our study. T cell lymphomas
occurred in the mice and were primarily caused by the uncorrected
Artemis-deficient background and not attributable to the effects of
the vector. There was no evidence of in vitro transformation in
the IVIM assay, although this assay essentially detects myeloid
transformation by vectors containing strong promoters.17 Similar
results were found in the IVIM assay with the ARTEMIS promoter
LV.12 Inflammation is a recognized feature of Artemis deficiency in
humans. Hypomorphic mutations and leaky phenotypes of Artemis
deficiency can cause Omenn syndrome associated with inflamma-240 Molecular Therapy: Methods & Clinical Development Vol. 15 December 2019tion.27 The production of circulating inflamma-
tory cytokines such as IFNg was recently re-
ported in Artemis-deficient subjects and was
linked to activation of neutrophils and NET for-
mation following oxidative stress.28 In our
study, we observed increased inflammatory cy-
tokines in the Artemis vector-treated mice, but
not in the Artemis-deficient non-treated con-
trols or in mice treated with WT cells. The levels
of cytokines observed in the vector-treated mice
were modest and did not cause visible behavior
change in the animals. Transgene toxicity can be
excluded because it should have manifested
earlier when high levels of ARTEMIS mRNA
were observed in the primary transplants, and
it did not. In addition, Artemis-transgenic
mice that can express up to 40 times the normal
levels of Artemis have no increased cytokinelevels or inflammation.22 Also, transplanting HSC overexpressing
ARTEMIS in C57BL/6 mice did not trigger inflammation (data
not shown). One hypothesis is that the inflammation observed in
the two-hit secondary transplanted animals was linked to a higher
peripheral CD4+ T cell reconstitution in these animals because
this was the only statistically significant difference compared with
one hit (Figure 4B). These cells could have been activated. Although
we failed to detect infectious pathogenic agents in the animal facility,
other non-tested agents including endogenous retroviruses could
have been involved. Alternatively, an imbalanced hematopoietic
reconstitution may hinder immune homeostasis via elevated
myeloid cells, which are prone to amplify inflammatory signals,
and indeed the mice had increased platelet counts and high
CD11b+ myeloid cell numbers in blood (data not shown). Inflam-
mation may have been caused by insufficient correction in Artemis
expression, as seen in patients with hypomorphic mutations.27
However, the levels of inflammation observed in mice seemed to
be lower than reported in Artemis-deficient individuals,28 and this
hypothesis is weakened by the fact that the observation was made
only in the group treated by two hits of vector in which reconstitu-
tion was at least as high as in the group treated with only one hit. We
conclude that the moderate and infra-clinical inflammation that was
observed in mice treated with two hits of the EF1a-hArtemis LV af-
ter secondary transplant is more likely due to an effect of the
model and by incomplete immune or hematopoietic homeostasis
accompanied by T cell activation than to an effect of the vector. In
Table 1. Tumor Analysis
Vector Category Group
Nb Mice with
Tumor Tumor Origin Characteristics of Donor-Derived Transduced Tumors
None controls ART_KO irr 7/20 (35%)





WT BM GFP 2/16 (12.5%)
2 tumors:
2 donor-derived, transduced
the 2 donor-derived tumors are localized thymomas




















2 host-derived, no vector
1 donor-derived, no vector
Disseminated T cell lymphoma, CD3highCD4+CD8+ cells vector
insertions in Jmjd1c; Dnah8; Dach2 genes gave rise to the two













the two donor-derived tumors are disseminated T cell lymphoma
both carrying the vector insertions in Jmjd1c; Dnah8; Dach2 genes
that match with the donor BM
www.moleculartherapy.orgRS-SCID patients treated by gene therapy, the immune follow-up is
likely to rapidly identify the occurrence of inflammatory responses,
should they occur.
Thus, altogether, the data presented here show that the EF1a-hAr-
temis LV permits a durable engraftment of hematopoietic progen-
itor cells in mice and reconstitutes their immune system without
vector-related adverse events. These results support further devel-
opment of this vector for future gene therapy in humans. Based on
the results of this murine study, high levels of engraftment should
be sought for optimal immune reconstitution; therefore, the infu-




Artemis-deficient (ART_KO) mice with a Dclre1c exon 12-deleted
allele on C57BL/6J background were reported previously8,29 and
were rederived by embryo transfer (Charles River) prior to the study
to ensure a non-leaky phenotype and lack of infection. The rederived
mice were bred and housed for experiments in a specific pathogen-
exempt environment at Genethon Animal Facility, Evry, France (na-
tional agreement D 91-228-107) in agreement with local guidelines
and national regulation. Animal health status monitoring of the facil-
ity was conducted several times during the study (Charles River). Ex-
periments were performed in accordance to international ethics prin-
ciples and the study was approved (CE10-005) by the local Animal
Ethical Committee.
Vector
The vesicular stomatitis virus G glycoprotein (VSVG)-pseudo-
typed EF1a-hArtemis vector was produced by transient transfec-
tion of HEK293T cells in Cell Factory 10 stacks (CF10). InMolecular Thebrief, 6 CF10 were transfected with pKLgagpol, pKRev, pKG,
and pEF1a-hArtemis plasmids. After a medium change,
Benzonase (1.13 U/mL) was added to the culture medium
(DMEM supplemented with 10% fetal calf serum [FCS] and
5 mM MgCl2) to remove plasmid and cellular DNA. After two
harvests, 12 L of supernatant was clarified, purified, and concen-
trated by anion exchange, tangential flow filtration, and gel filtra-
tion as previously reported.21 The final product was filtered
through 0.22 mm, aliquoted, and transferred to <70C for stor-
age. The lot was quality controlled before use and titered
2.3E+08 IG/mL (Infectious Genome/mL as defined on HCT116
cells). A PGK-eGPF LV encoding enhanced green fluorescent pro-
tein (eGFP) was produced an purified in the same conditions and
titered 7.8E+08 IG/mL.
Preparation andTransduction of ProgenitorCells for the Primary
Graft
BM cells were flushed from femurs and tibias of WT C57BL/6
mice and ART_KO male mice. The BM Sca-1+ cells were purified
from WT or ART_KO BM, using magnetic bead cell sorting (Mil-
tenyi Biotec). BMCs or BM_SCA+ cells were pre-activated over-
night by culture in X-vivo 20 medium (Lonza, Walkersville,
USA), 50 U/mL penicillin, 50 ng/mL streptomycin (PS)
(Invitrogen, Cergy Pontoise, France), murine IL-3 (20 ng/mL), hu-
man thrombopoietin (TPO) (100 ng/mL), human Flt-3 ligand
(100 ng/mL) (R&D Systems, Lille, France), and murine stem cell
factor (100 ng/mL) (Abcys, Paris, France), at 37C, 5% CO2. The
transduction of ART_KO BMCs or ART_KO BM SCA+ cells
(1E+6 cells/mL) was performed with 1E+8 infectious genomes
(i.g.)/mL of EF1a-hArtemis or PGK-GFP-WPRE vector (MOI
equivalent to 100) in the presence of protamine sulfate (6 mg/
mL) and cytokines for 6 h. Fresh medium was added, and cells
were washed. For the cells that received two hits of infection, arapy: Methods & Clinical Development Vol. 15 December 2019 241
Figure 8. Genotoxicity
Vector insertions in tumors or tissues (A) and IVIM assay (B). (A)
Vector genomic insertions were analyzed in BM, spleen, and
thymus of mice bearing tumors containing EF1a-hArtemis-LV-
transduced donor cells. The read counts are indicated in each
sample analyzed, and the percentage of reads for each IS is
represented by individual colors, with gray representing IS with
less than 3% of relative abundance. Samples are identified by
mouse number and tissue (BM=bone marrow), SPL (spleen) and
THY (thymus). (B) Insertional mutagenesis leads to clonal
outgrowth after low-density seeding in the IVIM assay. Non-
immortalized cells do not grow (negative, below limit of detection
[LOD]). The number of wells containing insertion mutants is used
to calculate the replating frequency (RF) according to Poisson
statistics. Assays with an RF R 3.17  104 (Q1 level) are
counted as positive. Each dot represents one assay. In the three
experiments, we obtained immortalized clones from the cells
transduced by the positive control vectors RSF91 or LV-SF,
whereas all plates containing EF1a-Artemis transduced cells
were below the Q1 level. Horizontal bars represent mean values.
Molecular Therapy: Methods & Clinical Developmentsecond exposure of vector was performed overnight in the pres-
ence of protamine sulfate (6 mg/mL) and cytokines. Fresh medium
was added, and cells were washed. One part of cells was injected in
the mice and the other part was expanded for 7 days in the pres-
ence of cytokines in a humidified atmosphere (37C, 5% CO2 in
air) and was plated in MethoCult medium (H3434; STEMCELL
Technologies, Vancouver, CA, USA). After 1 week, CFU-E/
BFU-E, CFU-GM, and CFU-GEMM were counted by microscopy,
and individual colonies were collected and genomic DNA (gDNA)
was extracted to measure VCN. Seven days post-infection, the ef-
ficiency of transduction was evaluated in the population of cells
expanded in vitro from Sca1+ cells with cytokines and in individual
CFCs by qRT-PCR to detect VCN. qRT-PCR was performed to
measure ARTEMIS transcript levels in the population of cells
expanded in vitro from Sca-1+ cells.242 Molecular Therapy: Methods & Clinical Development Vol. 15 December 2019Transplantation of Progenitor Cells
One day post-infection, the transduced progenitor
cells (2E+5 cells/mouse) were injected intrave-
nously (retro-orbital) into irradiated ART_KO fe-
males. Recipient female ART_KO mice were irra-
diated in ventilated plexiglass containers using an
X-ray source at a dosage rate of 0.84 Gy/min
(Faxitron CP160). Total body irradiation was
given as a single exposure of 3 Gy at 2–3 h before
cell transplantation.
Preparation of BM Cells for the Secondary Graft
After isoflurane anesthesia, mice from primary graft
were killed by cervical dislocation and their femur
and tibias removed to flush BMCs. One part of cells
was used for the secondary transplant, and the other
part was used for different analyses (VCN, mRNA
expression, immune-phenotype, and insertion siteanalyses for mice with tumors). For the secondary graft, BMCs
(1E+7 cells) from each mouse from the primary graft were injected
intravenously into two irradiated Artemis-deficient females. Recipient
female ART_KO mice were irradiated as described above for primary
transplants.
Evaluation of Transduction, Engraftment, and Transgene
Expression in Treated Mice
Mice were regularly observed during the protocol and, if needed, were
sacrificed before the end of the protocol and autopsied. At 3 and
6 months (at sacrifice) after transplantation, blood was sampled by
retro-orbital puncture (200 mL of blood with citrate 3.8%: 1/10 vol).
At the endpoint (6 months post-transplantation), remaining live mice
were killed by cervical dislocation and following macroscopic analysis,
organs were taken for histopathological analysis. BMCs were obtained
www.moleculartherapy.orgafter flushing. Cell suspensions from lymph nodes, spleen, and thymus
were obtained by passing the disrupted tissue through a 40-mm filter in
PBS buffer. The efficiency of transduction was evaluated by measuring
VCN using qPCR. Male donor cell engraftment into female recipient
micewas evaluated using qPCR of amale Y sequence calibrated on a se-
ries of genomic DNA samples prepared from varying proportions of
male/female blood cells, as previously described.20
Genomic DNA was extracted from spleen, BM, thymus, and lymph
node. For greater than 1E+6 cells, the “Wizard genomic DNA purifi-
cation kit” (Promega Corporation, Madison, WI, USA) was used.
When cell quantity was inferior to 1E+6 cells, Proteinase K extraction
was performed. The “QIAamp DNA Blood Mini kit” was used for
gDNA extraction from peripheral blood cells, and the “DNeasy Blood
& Tissue Kit” (QIAGEN, Hilden, Germany) for gDNA extraction
from ovary.
Total RNA from spleen, BM, thymus, and lymph node was ex-
tracted using the SV total RNA isolation system (Promega). One
microgram of each total RNA sample was reverse transcribed
into cDNA with the SuperScript II RT (GIBCO BRL) using
random hexamer primers at 42C for 50 min. The RT was inacti-
vated by incubation for 15 min at 70C.
All primers and probes used are listed in Table S6. Oligonucleotide
primers and TaqMan probes (with a 50 reporter dye [6-carboxyfluor-
escein] and a downstream 30 quencher dye [6-carboxytetramethyl
rhodamine]) were designed with Primer Express and Oligo 4.0
Primer Analysis software (Perkin Elmer Applied Biosystem). qPCR
was performed as previously reported.24 All measures were per-
formed at least in duplicate. Negative controls were included in
each analysis. Data were edited using the Primer Express software.
VCN was measured by PCR quantification of HIV-Psi sequence per
cell in reference to the murine TTN gene. Results were expressed as
copies of vector per cell and calculated from a standard curve based
on dilutions of a plasmid containing both the HIV-Psi and mouse
TTN sequences. Donor chimerism or Y-Chimerism was measured
by PCR quantification of murine Y sequence per cell in reference to
the murine Ttn gene. Results were expressed as percentages of male
cells in the population of cells tested. Percentages of Y-chimerism
were calculated by qPCR using a reference titration curve consisting
of varying proportions of male and female blood cells. ARTEMIS
mRNA was measured by qRT-PCR in reference to murine TfIId
gene expression and this ratio was normalized to the ratio of murine
Artemis/TfIId using a standard that consists of gDNA from murine
WT cells spiked with a plasmid containing a copy each of murine
and human Artemis transgene sequences. Using this standard, WT
murine cells provided the 100% value.
Flow Cytometry
Antibodies used for the study are listed in Table S7. Stainings were
done after Fc blocking. Cells were analyzed with the Beckman Coulter
FC 500 using the Kaluza version 1.2 software. At 3 and 6months post-
transplantation, lysed peripheral blood cells were stained with theMolecular Thefollowing multicolor antibody panels: CD3-allophycocyanin (APC),
CD4-PECy7, CD8-ECD/IgM APC, CD19-PECy7, IgD-PE/CD11b
APC, TCRab-PE-Cy7, and NK1.1 PE. Thymus cells were stained by
CD3-APC, CD4 PE-Cy7, CD8-ECD and CD4-PECy7, CD8-ECD,
CD44-PE, and CD25-APC. Lymph node cells were stained by CD3-
APC, CD4 PE-Cy7, CD8-ECD/IgM APC, CD19-PECy7, and IgD-
PE. Cells from spleen were stained with the same panel as lymph
node and in addition by CD11b APC, TCRab-PE-Cy7, NK1.1 PE,
and TCRgd-PE-CY7. Cells from BM were stained by CD3-APC,
CD4 PE-Cy7, CD8-ECD; IgM APC, CD19-PECy7, IgD-PE; and
CD11b APC, TCRab-PE-Cy7, NK1.1 phycoerythrin (PE).
Combinatorial Diversity Analysis (Multiplex PCR Assay)
Mouse TCR diversity was measured by ImmunID (ImmunID Tech-
nologies, Grenoble, France) using a patented multi-N-plex qPCR
technology to detect and characterize V-J rearrangements of the
T and B cell receptor at the genomic DNA level from cells of spleen
or thymus. The assay allows the simultaneous detection of several
V-J rearrangements in the same reaction and covers 100% of the
possible combinatorial rearrangements. Results of immune diversity
are expressed as a percentage. This percentage represents the number
of detected V-J rearrangements compared with the maximum num-
ber of possible recombinations between V families and J segments.
Serum Analysis for Ig and Cytokine Quantification
Mouse IgM and IgG levels were measured by quantifying serial dilu-
tions of serum samples with an ELISA kit (quantification ELISA kit;
Bethyl, Montgomery, TX, USA), according to the manufacturer’s
instructions.
Inflammatory cytokines were measured in selected mouse sera by Cy-
tometric Bead Array mouse inflammation Kit (BD reference 552364)
using 1:5 dilution of serum. The BD CBA Mouse Inflammation Kit
can be used to quantitatively measure IL-6, IL-10, monocyte chemo-
attractant protein-1 (MCP-1), IFN-g, TNF, and IL-12p70 (IL-12p70)
protein levels in a single sample. The kit performance has been opti-
mized for analysis of specific proteins in tissue culture supernatants,
EDTA plasma, and serum samples. The kit limit of detection provided
by the manufacturer is 5 pg/mL for IL-6, 17.5 pg/mL for IL-10,
52.7 pg/mL for MCP-1, 2.5 pg/mL for IFN-g, 7.3 pg/mL for TNF,
and 10.7 pg/mL for IL-12p70.
Histological Evaluation
Tissues removed from euthanized animals was fixed in 10% formalin
and embedded in paraffin. Tissue sections (4 mm) were stained with
H&E for histological examination. Immunostaining was performed
for the spleen (CD3+, B220+) and thymus (CD3+). Analysis and inter-
pretation of the results were verified by an independent outside
contractor, Biodoxis.
Blood Counts
Blood samples were analyzed for standard hematological parameters
(WBC counts, RBC, hemoglobin, hematocrit, and platelet counts) us-
ing an MS9.3 counter (Schloessing Melet, Cergy-Pontoise, France).rapy: Methods & Clinical Development Vol. 15 December 2019 243
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LV integration sites (IS) have been recovered, processed, and mapped
as previously described.24 In brief, genomic DNA extracted from either
BM, thymus, and spleen was digested with Tru9I restriction enzyme,
and LTR vector-genome junctions were amplified by LM-PCR. Nested
PCRs were performed with specific primers annealing to the linker and
the 30 vector LTR adapted to Illumina sequencing and containing a 4-
bp sample-specific barcode for sample identification. Libraries were
quantified and loaded on a 1% agarose gel, and amplicons ranging
from 200 to 500 kb were manually extracted from the gel, purified,
and processed with MiSeq Reagent Kit v3, barcoded with a 6-bp sam-
ple-specific tag, and sequenced to saturation on an Illumina MySeq
machine at IGA Technology Services (Udine, Italy). Raw reads were
bioinformatically trimmed to recover the murine genome sequences
adjacent to the 30 proviral LTR by the Skewer software (mismatch
rate of 0.12, minimal length of 20 bp after trimming, and a minimal
match length equal to the pre-trimming sequence), and mapped on
the reference genome (murine GRCm38/mm10) with the Bowtie2
software (>95% identity). The genomic coordinates of the first nucle-
otide in the host genome adjacent to the viral LTR were indicated as IS.
ISs identified by different reads as mapping in the same genomic posi-
tion were collapsed, and the number of corresponding reads defined
the read counts. Genes having the IS inside the gene (defined as the
most upstream TSS and the most downstream end of gene, in case
of multiple isoforms) were annotated as target genes.
In Vitro Immortalization Assay
The method has been previously reported.17 In brief, after transduc-
tion, WT lineage-negative cells were expanded as mass cultures for
2 weeks in Iscove's Modified Dulbecco's Medium (IMDM) containing
50 ng/mL murine stem cell factor (mSCF), 100 ng/mL hFlt-3 ligand,
100 ng/mL hIL-11, 10 ng/mL, mIL-3, 10% FCS, 1% penicillin/strep-
tomycin, and 2 mM glutamine. After mass culture expansion, cells
were seeded into 96-well plates at a density of 100 cells per well.
Two weeks later, wells containing actively proliferating cells were
counted microscopically and by absorbance measurement of a
reduced formazan (MTT assay) in a microplate reader. The replating
frequency (RF) of insertional mutants was calculated based on Pois-
son statistics using the L-Calc software (STEMCELL Technologies,
Vancouver, BC, Canada). Plates with an RF R 3.17  104 were
defined as positive assays.
Statistical Analyses
The non-parametric Mann-Whitney test was used (GraphPad soft-
ware) to compare groups.
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